WO1993014760A3 - Methods - Google Patents

Methods Download PDF

Info

Publication number
WO1993014760A3
WO1993014760A3 PCT/US1993/000730 US9300730W WO9314760A3 WO 1993014760 A3 WO1993014760 A3 WO 1993014760A3 US 9300730 W US9300730 W US 9300730W WO 9314760 A3 WO9314760 A3 WO 9314760A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
methods
hiv
delaying
aids
Prior art date
Application number
PCT/US1993/000730
Other languages
French (fr)
Other versions
WO1993014760A2 (en
Inventor
Alison Mary Badger
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Priority to AU35951/93A priority Critical patent/AU666175B2/en
Priority to EP93904671A priority patent/EP0624089A4/en
Priority to US08/256,708 priority patent/US5482959A/en
Priority to KR1019940702596A priority patent/KR950700068A/en
Priority to JP5513407A priority patent/JPH07503252A/en
Publication of WO1993014760A2 publication Critical patent/WO1993014760A2/en
Publication of WO1993014760A3 publication Critical patent/WO1993014760A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Invented is a method of preventing or delaying the occurrence of acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV) seropositive humans which comprises administering to such human an effective therefor amount of a substituted azaspirane.
PCT/US1993/000730 1992-01-28 1993-01-27 Methods WO1993014760A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU35951/93A AU666175B2 (en) 1992-01-28 1993-01-27 A method for delaying HIV induced AIDS by administration of substituted azasperane compounds
EP93904671A EP0624089A4 (en) 1992-01-28 1993-01-27 Methods.
US08/256,708 US5482959A (en) 1992-01-28 1993-01-27 Method for delaying aids in an HIV infected individual by administration of substituted azaspirane compounds
KR1019940702596A KR950700068A (en) 1992-01-28 1993-01-27 A method for delaying HIV in-duced AIDS by administration of substituted azasperane compounds by administering a substituted azaspiran compound
JP5513407A JPH07503252A (en) 1992-01-28 1993-01-27 Method for delaying HIV-induced AIDS by administration of substituted azasperane compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9201803.5 1992-01-28
GB929201803A GB9201803D0 (en) 1992-01-28 1992-01-28 Methods

Publications (2)

Publication Number Publication Date
WO1993014760A2 WO1993014760A2 (en) 1993-08-05
WO1993014760A3 true WO1993014760A3 (en) 1993-09-02

Family

ID=10709398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/000730 WO1993014760A2 (en) 1992-01-28 1993-01-27 Methods

Country Status (7)

Country Link
EP (1) EP0624089A4 (en)
JP (1) JPH07503252A (en)
KR (1) KR950700068A (en)
AU (1) AU666175B2 (en)
CA (1) CA2128535A1 (en)
GB (1) GB9201803D0 (en)
WO (1) WO1993014760A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9315351D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315340D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315306D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US181704A (en) * 1876-08-29 Improvement in flour-dressing machines
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
JPH06501468A (en) * 1990-09-24 1994-02-17 スミスクライン・ビーチャム・コーポレイション Method
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 111, No. 17, Abstract No. 153616r, issued 23 October 1989, (Columbus, Ohio, USA), BADGER et al., "Preparation of N-Aminoakyl-2-Azaspiro(4.5)Decanes and Analogs as Immunosuppressants", (Dept. Immumol., SmitKline Beckmann Corp., King of Prussia, PA 19406-0939 USA); & EP,A,310 *
CHEMICAL ABSTRACTS, Volume 113, No. 21, Abstract No. 191085r, issued 19 November 1990, (Columbus, Ohio, USA), BADGER et al., "Antiarthritic and Suppressor Cell Inducing Activity of Azaspiranes: Structure-Function Relationships of a Novel Class of Immunomodulatory Agents", (Dept. Immumol., SmithKline and French Lab., King of *
CHEMICAL ABSTRACTS, Volume 86, No. 9, Abstract No. 55229n, issued 28 February 1977, (Columbus, Ohio, USA), EL-TELBANY et al., "Synthesis of Certain Spiro Compounds for Pharmacological Study. Part II", (Fac. Pharm., Cairo, Egypt); & J. PHARM. BELG., 1976, 31(4), pp. 403-10. *
See also references of EP0624089A4 *

Also Published As

Publication number Publication date
JPH07503252A (en) 1995-04-06
EP0624089A1 (en) 1994-11-17
KR950700068A (en) 1995-01-16
WO1993014760A2 (en) 1993-08-05
AU3595193A (en) 1993-09-01
CA2128535A1 (en) 1993-08-05
AU666175B2 (en) 1996-02-01
GB9201803D0 (en) 1992-03-11
EP0624089A4 (en) 1994-12-14

Similar Documents

Publication Publication Date Title
WO1996006620A3 (en) Lipid analogs for treating viral infections
AU2045192A (en) Compounds and methods for inhibition of hiv and related viruses
EP0831873A4 (en) The treatment of hiv and other viral infections using combinatory therapy
AU4019289A (en) Hiv protease inhibitors useful for the treatment of aids
NO905428L (en) PROCEDURE FOR THE PREPARATION OF HIV PROTEASE INHIBITORS FOR TREATMENT OF AIDS.
EP0276279A4 (en) Composition of matter and method of immunizing against viral causative agents of aids and arc.
AU4028895A (en) Vaccine and treatment method of Human Immunodeficiency Virus
AU8693491A (en) Synergism of hiv reverse transcriptase inhibitors
AU6774294A (en) Methods of preventing viral replication
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
AU5848794A (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
AU1308188A (en) Methods of treating acquired immune deficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV)
WO1993014760A3 (en) Methods
AU3530293A (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)
WO1990013281A3 (en) Method of suppressing hiv infection
AU1193988A (en) Method of inhibiting the transmission of aids virus
AU7212694A (en) Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
AU2833789A (en) Non-reverting rna viruses
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AU4829190A (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
ZA945416B (en) Method of inhibiting the production of infectious human immunodeficiency viruses (HIV) in HIV seropositive humans.
ZA945418B (en) Method of inhibiting the replication of human immunodeficiency viruses (HIV) in HIV seropositive humans.
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
ZA945417B (en) Method of inhibiting cellular entry of human immunodeficiency viruses NHIV) in HIV seropositive humans.
AU5000796A (en) Process for the deactivation of hiv and other viruses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2128535

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 08256708

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1993904671

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993904671

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993904671

Country of ref document: EP